Clinical Scorecard: Clinical Features and Associated Risk Factors of Protein-Losing Enteropathy: A Retrospective Analysis
At a Glance
Category
Detail
Condition
Protein-Losing Enteropathy (PLE)
Key Mechanisms
Excessive gastrointestinal protein loss due to intestinal mucosal injury or impaired lymphatic drainage.
Target Population
Patients diagnosed with PLE, particularly those with connective tissue disease-associated PLE (CTD-PLE) and lymphatic drainage disorder-associated PLE (LDD-PLE).
Care Setting
Hospitalized patients at Beijing Shijitan Hospital.
Key Highlights
CTD-PLE patients are older and predominantly female compared to LDD-PLE patients.
Common manifestations include edema (84.2%) and serous cavity effusions (76.7%).
CTD-PLE shows distinct laboratory features such as higher total cholesterol and D-dimer levels.
Glucocorticoids plus immunosuppressants lead to symptom remission in CTD-PLE patients.
LDD-PLE patients more frequently experience diarrhea and lower lymphocyte counts.
Guideline-Based Recommendations
Diagnosis
Use scintigraphy for confirmation of PLE.
Consider clinical features and laboratory findings for etiologic differentiation.
Management
CTD-PLE may respond to glucocorticoids and immunosuppressants.
Surgical intervention may be necessary for LDD-PLE.
Monitoring & Follow-up
Regular follow-up to assess symptom remission and laboratory markers such as albumin levels.
Risks
Increased risk of thrombosis in CTD-PLE patients.
Potential for malnutrition and infection due to protein loss.
Patient & Prescribing Data
146 patients with confirmed PLE, including 30 with CTD-PLE and 116 with LDD-PLE.
19 out of 20 CTD-PLE patients treated with glucocorticoids plus immunosuppressants achieved symptom remission.
Clinical Best Practices
Utilize age at onset, hemoglobin, and total cholesterol as predictors for CTD-PLE.
Differentiate between etiologies based on clinical and laboratory features.
